SARTORIUS AG VZ

ISIN: **DE0007165631** WKN: **716563** Asset Class: **Stock**



Company Profile

Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	22	20	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	1,956,900,000		2,023,200,000		1,796,802,000	
Common stock capital		68,400,000		68,400,000		68,416,000
Fixed assets	7,824,400,000		4,972,500,000		3,922,875,000	
Equity capital of a company		2,757,400,000		2,658,900,000		1,720,196,000
Cash and cash equivalents	379,200,000		165,900,000		342,809,000	
Accrued liabilities		78,100,000		77,700,000		88,713,000
Other assets	-		-		-	
Current liabilities		1,329,900,000		1,803,300,000		1,547,164,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		5,694,000,000		2,533,500,000		2,452,317,000
Different income		-		-		-
Other liabilities		113,900,000		216,400,000		421,818,000
Total assets	9,781,300,000	9,781,300,000	6,995,700,000	6,995,700,000	5,719,677,000	5,719,677,000

D -		
ва	ıance	notes
_ ~		

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	14,614	15,942	13,832
Equity ratio	35.25%	47.57%	38.12%
Debt-equity ratio	183.72%	110.21%	162.36%

_	41	L	_	
	П	п	e	II C

	2023	2022	2021
Tax Expense Rate	24.44%	22.73%	36.12%

SARTORIUS AG VZ

ISIN: **DE0007165631** WKN: **716563** Asset Class: **Stock**

Income statement			
	2023	2022	2021
Turnover	3,395,700,000	4,174,700,000	3,449,222,000
Net income	205,200,000	678,100,000	318,888,000
EBIT	573,200,000	1,248,600,000	713,552,000
Operating income before taxes	392,400,000	1,181,700,000	668,423,000
Cash Flow	745,800,000	698,600,000	841,697,000
Net interest income	-180,800,000	-66,900,000	-45,129,000
Research and development expenses	170,800,000	177,800,000	139,881,000
Income taxes	95,900,000	268,600,000	241,445,000
Result from investments in subsidaries, associates and other	-6,500,000	0	0
Revenues per employee	232,359	261,868	249,365

Chairman of Supervisory Board
Member of Supervisory Board

Members of Management Board		
Chairman of Managing Board		
Member of Executive Committee		